• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.RNA 聚合酶β亚基(rpoB)突变促进 Mu3 株 hVISA 至 VISA 表型转化。
Antimicrob Agents Chemother. 2011 Sep;55(9):4188-95. doi: 10.1128/AAC.00398-11. Epub 2011 Jul 11.
2
Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.在对万古霉素敏感的金黄色葡萄球菌中完全重建菌株Mu50的万古霉素中介金黄色葡萄球菌表型。
Antimicrob Agents Chemother. 2016 May 23;60(6):3730-42. doi: 10.1128/AAC.00420-16. Print 2016 Jun.
3
"Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.“慢VISA”,一种新型万古霉素耐药表型,在体外异质性万古霉素中介金黄色葡萄球菌菌株Mu3中发现。
Antimicrob Agents Chemother. 2014 Sep;58(9):5024-35. doi: 10.1128/AAC.02470-13. Epub 2014 May 19.
4
Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.对源自异质性万古霉素中介金黄色葡萄球菌(hVISA)临床菌株Mu3的实验室诱导VISA菌株中导致hVISA向VISA转化的突变进行全面鉴定。
Antimicrob Agents Chemother. 2013 Dec;57(12):5843-53. doi: 10.1128/AAC.00425-13. Epub 2013 Sep 9.
5
Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.突变的反应调节因子graR负责金黄色葡萄球菌从异质性万古霉素中介耐药性转变为万古霉素中介耐药性。
Antimicrob Agents Chemother. 2008 Jan;52(1):45-53. doi: 10.1128/AAC.00534-07. Epub 2007 Oct 22.
6
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.亚胺培南对异质性万古霉素中介金黄色葡萄球菌的选择作用
Antimicrob Agents Chemother. 2009 Aug;53(8):3190-6. doi: 10.1128/AAC.00834-08. Epub 2009 May 18.
7
A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".RNA聚合酶β'亚基(RpoC)的突变将异质性万古霉素中介金黄色葡萄球菌(hVISA)转变为“迟缓VISA”。
Antimicrob Agents Chemother. 2015 Jul;59(7):4215-25. doi: 10.1128/AAC.00135-15. Epub 2015 May 4.
8
walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.walK 和 clpP 突变导致金黄色葡萄球菌对万古霉素的敏感性降低。
Antimicrob Agents Chemother. 2011 Aug;55(8):3870-81. doi: 10.1128/AAC.01563-10. Epub 2011 May 31.
9
VraR Binding to the Promoter Region of Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.VraR与 的启动子区域结合会抑制其在万古霉素中介金黄色葡萄球菌(VISA)和异质性VISA中的功能。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02740-16. Print 2017 May.
10
Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus.终止密码子在耐甲氧西林金黄色葡萄球菌的发育和万古霉素不敏感性丧失中的作用。
J Antimicrob Chemother. 2012 Sep;67(9):2101-6. doi: 10.1093/jac/dks171. Epub 2012 May 29.

引用本文的文献

1
Allele-Specific Effects of Mutations in the Rifampin Resistance-Determining Region (RRDR) of RpoB on Physiology and Antibiotic Resistance in .RpoB的利福平耐药决定区(RRDR)突变对[具体对象]生理学和抗生素耐药性的等位基因特异性影响
bioRxiv. 2025 Aug 4:2025.07.25.666922. doi: 10.1101/2025.07.25.666922.
2
rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis.临床表皮葡萄球菌中rpoB基因突变及其与利福平耐药性的关联
J Antimicrob Chemother. 2025 Apr 2;80(4):1067-1071. doi: 10.1093/jac/dkaf035.
3
The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence.利福平在人工关节感染中的作用:疗效、挑战及临床证据
Antibiotics (Basel). 2024 Dec 17;13(12):1223. doi: 10.3390/antibiotics13121223.
4
Metabolic remodeling by RNA polymerase gene mutations is associated with reduced β-lactam susceptibility in oxacillin-susceptible MRSA.RNA 聚合酶基因突变导致的代谢重塑与耐苯唑西林金黄色葡萄球菌中β-内酰胺类药物敏感性降低有关。
mBio. 2024 Jun 12;15(6):e0033924. doi: 10.1128/mbio.00339-24. Epub 2024 May 2.
5
Staph wars: the antibiotic pipeline strikes back.葡萄球菌之战:抗生素管道奋起反击。
Microbiology (Reading). 2023 Sep;169(9). doi: 10.1099/mic.0.001387.
6
Identification and Characterization of a Vancomycin Intermediate-Resistant Isolated from Guangzhou, China.从中国广州分离出的耐万古霉素中间型菌株的鉴定与特性分析。
Infect Drug Resist. 2023 Jun 8;16:3639-3647. doi: 10.2147/IDR.S411860. eCollection 2023.
7
Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus.抗微生物肽和小分子靶向金黄色葡萄球菌的细胞膜。
Microbiol Mol Biol Rev. 2023 Jun 28;87(2):e0003722. doi: 10.1128/mmbr.00037-22. Epub 2023 Apr 27.
8
New Antimicrobial Resistance Strategies: An Adaptive Resistance Network Conferring Reduced Glycopeptide Susceptibility in VISA.新型抗菌耐药策略:一种赋予万古霉素中介金黄色葡萄球菌(VISA)降低糖肽类药物敏感性的适应性耐药网络
Antibiotics (Basel). 2023 Apr 19;12(4):783. doi: 10.3390/antibiotics12040783.
9
Multidrug Resistance Plasmid pTZC1 Could Be Pooled among Strains on the Skin Surface.多重耐药质粒pTZC1可在皮肤表面菌株间聚集。
Microbiol Spectr. 2023 Feb 27;11(2):e0362822. doi: 10.1128/spectrum.03628-22.
10
CID12261165, a flavonoid compound as antibacterial agents against quinolone-resistant Staphylococcus aureus.CID12261165,一种黄酮类化合物,用作抗喹诺酮类耐药金黄色葡萄球菌的抗菌剂。
Sci Rep. 2023 Jan 31;13(1):1725. doi: 10.1038/s41598-023-28859-8.

本文引用的文献

1
Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.rpoB 基因突变对金黄色葡萄球菌万古霉素低敏性的影响。
J Clin Microbiol. 2011 Jul;49(7):2680-4. doi: 10.1128/JCM.02144-10. Epub 2011 Apr 27.
2
An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.RpoB 突变赋予金黄色葡萄球菌对达托霉素和万古霉素的双重异质性耐药性。
Antimicrob Agents Chemother. 2010 Dec;54(12):5222-33. doi: 10.1128/AAC.00437-10. Epub 2010 Sep 13.
3
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.亚胺培南对异质性万古霉素中介金黄色葡萄球菌的选择作用
Antimicrob Agents Chemother. 2009 Aug;53(8):3190-6. doi: 10.1128/AAC.00834-08. Epub 2009 May 18.
4
Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance.金黄色葡萄球菌中依赖于σB的yabJ-spoVG操纵子的功能表征:在耐甲氧西林和耐糖肽中的作用
Antimicrob Agents Chemother. 2009 May;53(5):1832-9. doi: 10.1128/AAC.01255-08. Epub 2009 Feb 17.
5
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.vraSR和graSR点突变对万古霉素中介金黄色葡萄球菌万古霉素耐药性的作用
Antimicrob Agents Chemother. 2009 Mar;53(3):1231-4. doi: 10.1128/AAC.01173-08. Epub 2009 Jan 5.
6
Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus.通过基因组和遗传分析鉴定出在金黄色葡萄球菌对中间糖肽耐药性中起关键作用的两个新基因。
Antimicrob Agents Chemother. 2009 Mar;53(3):903-11. doi: 10.1128/AAC.01287-08. Epub 2008 Dec 22.
7
Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics.MgrA和SarA在耐甲氧西林金黄色葡萄球菌自溶及对细胞壁活性抗生素耐药中的作用。
J Infect Dis. 2009 Jan 15;199(2):209-18. doi: 10.1086/595740.
8
Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus.利奈唑胺对万古霉素中介金黄色葡萄球菌抗菌活性的增强
Antimicrob Agents Chemother. 2008 Nov;52(11):4207-8. doi: 10.1128/AAC.00676-08. Epub 2008 Aug 18.
9
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus.基因组分析揭示了双组分传感器基因graS中的一个点突变,该突变导致临床金黄色葡萄球菌对万古霉素产生中度耐药性。
Antimicrob Agents Chemother. 2008 Oct;52(10):3755-62. doi: 10.1128/AAC.01613-07. Epub 2008 Jul 21.
10
The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses.GraRS调控系统控制着金黄色葡萄球菌对抗菌宿主防御的敏感性。
BMC Microbiol. 2008 Jun 2;8:85. doi: 10.1186/1471-2180-8-85.

RNA 聚合酶β亚基(rpoB)突变促进 Mu3 株 hVISA 至 VISA 表型转化。

Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

机构信息

Department of Bacteriology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.

出版信息

Antimicrob Agents Chemother. 2011 Sep;55(9):4188-95. doi: 10.1128/AAC.00398-11. Epub 2011 Jul 11.

DOI:10.1128/AAC.00398-11
PMID:21746940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3165293/
Abstract

The clinical vancomycin-intermediate Staphylococcus aureus (VISA) strain Mu50 carries two mutations in the vraSR and graRS two-component regulatory systems (TCRSs), namely, vraS(I5N) and graR(N197S) (hereinafter designated graR). The clinical heterogeneously vancomycin-intermediate S. aureus (hVISA) strain Mu3 shares with Mu50 the mutation in vraS that encodes the VraS two-component histidine kinase. Previously, we showed that introduction of the plasmid pgraR, carrying the mutated two-component response regulator graR, converted the hVISA strain Mu3 into VISA (vancomycin MIC = 4 mg/liter). Subsequently, however, we found that the introduction of a single copy of graR into the Mu3 chromosome by a gene replacement method did not confer on Mu3 the VISA phenotype. The gene-replaced strain Mu3graR thus obtained remained hVISA (MIC ≤ 2 mg/liter), although a small increase in vancomycin MIC was observed compared to that of the parent strain Mu3. Reevaluation of the Mu3 and Mu50 genomes revealed the presence of another mutation responsible for the expression of the VISA phenotype in Mu50. Here, we demonstrate that in addition to the two regulator mutations, a third mutation found in the Mu50 rpoB gene, encoding the RNA polymerase β subunit, was required for Mu3 to achieve the level of vancomycin resistance of Mu50. The selection of strain Mu3graR with rifampin gave rise to rpoB mutants with various levels of increased vancomycin resistance. Furthermore, 3 (33%) of 10 independently isolated VISA strains established from the heterogeneous subpopulations of Mu3graR were found to possess rpoB mutations with or without an accompanying rifampin-resistance phenotype. The data indicate that a sizable proportion of the resistant hVISA cell subpopulations is composed of spontaneous rpoB mutants with various degrees of increased vancomycin resistance.

摘要

临床万古霉素中介金黄色葡萄球菌(VISA)菌株 Mu50 携带 vraSR 和 graRS 双组分调节系统(TCRS)中的两个突变,即 vraS(I5N)和 graR(N197S)(以下称为 graR)。临床异质性万古霉素中介金黄色葡萄球菌(hVISA)菌株 Mu3 与 Mu50 共享编码 VraS 双组分组氨酸激酶的 vraS 突变。先前,我们表明,引入携带突变的双组分应答调节子 graR 的质粒 pgraR,将 hVISA 菌株 Mu3 转化为 VISA(万古霉素 MIC = 4 毫克/升)。然而,随后我们发现,通过基因替换方法将单个拷贝的 graR 引入 Mu3 染色体中,并未使 Mu3 获得 VISA 表型。因此,获得的基因替换菌株 Mu3graR 仍然是 hVISA(MIC ≤ 2 毫克/升),尽管与亲本菌株 Mu3 相比,万古霉素 MIC 略有增加。对 Mu3 和 Mu50 基因组的重新评估表明,存在另一个突变,该突变负责 Mu50 中 VISA 表型的表达。在这里,我们证明,除了两个调节子突变外,Mu50 的 rpoB 基因中发现的第三个突变,编码 RNA 聚合酶β亚基,也是 Mu3 达到 Mu50 水平的万古霉素抗性所必需的。用利福平选择 Mu3graR 菌株导致 rpoB 突变体具有不同水平的万古霉素抗性增加。此外,从 Mu3graR 的异质亚群中分离出的 10 个独立的 VISA 菌株中有 3 个(33%)被发现具有 rpoB 突变,这些突变要么带有伴随的利福平耐药表型,要么没有。这些数据表明,相当一部分耐药 hVISA 细胞亚群由具有不同程度增加的万古霉素抗性的自发 rpoB 突变体组成。